IOVS Am. J. Pathology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2006;47:4856-4859.)
© 2006 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.06-0014
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gutiérrez-Ortiz, C.
Right arrow Articles by Bolivar, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gutiérrez-Ortiz, C.
Right arrow Articles by Bolivar, G.

Short-Term Effects of Latanoprost on Anterior Chamber Depth in Patients with Glaucoma or Ocular Hypertension

Consuelo Gutiérrez-Ortiz,1 Miguel A. Teus,1,2,3 and Gema Bolivar1

1From the Hospital Universitario Príncipe de Asturias, Carretera Meco s/n, Alcalá de Henares, Madrid, Spain; 2Universidad de Alcalá, Carretera de Meco s/n, Alcalá de Henares, Madrid, Spain;and 3VISSUM Hospital Oftalmológico de Madrid, Madrid, Spain.

PURPOSE. Prostaglandin F2{alpha} analogues, such as latanoprost, may cause a decrease in the extracellular matrices, such as collagen, and changes in fibrillin-1; both are components of the ciliary zonules. However, the mechanical effect of these changes on the dynamics of the ciliary zonules is unknown. This study was conducted to evaluate the effect of latanoprost 0.005% on anterior chamber depth (ACD), best corrected visual acuity (BCVA), lens thickness, and anterior chamber dynamics in patients with glaucoma or ocular hypertension.

METHODS. This was a prospective, nonrandomized, autocomparative trial that included 40 patients (40 eyes) with glaucoma or ocular hypertension. ACD was measured with ultrasonography before and after 1 month of treatment with latanoprost. In addition, ACD was measured before and 1 hour after instillation of pilocarpine 2% at baseline and 1 month after treatment with latanoprost. To assess the reproducibility of the ultrasonic measurements, a control group of 20 patients (20 eyes) who did not receive latanoprost was also analyzed.

RESULTS. The mean ACD before treatment with latanoprost and before the instillation of pilocarpine was 3.14 ± 0.46 mm (SD) and after the instillation of pilocarpine, 3.04 ± 0.46 mm (SD). After 1 month of treatment with latanoprost, ACD was 2.98 ± 0.44 mm (SD) before instillation of pilocarpine and 2.91 ±0.49 mm (SD) after instillation of pilocarpine. P ≤ 0.05 was reached for all comparisons.

CONCLUSIONS. These findings suggest that latanoprost decreases ACD in patients with glaucoma or ocular hypertension after 1 month of treatment.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Association for Research in Vision and Ophthalmology